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ABSTRACT 
 
Cancer is the most frequent reason of death in humans after heart disease. Most 
of the cancers are caused by mutations in tumor suppressor genes that play distinct roles 
in tumor formations. If a tumor suppressor gene is mutated, it loses its function to 
control cell division which may lead to overgrowth of cells that leads to tumor 
formation. It is important to identify the genes involved in tumor formation and 
metastasis to develop new cancer prevention and treatment methods.  
In a previous study, differentially expressed genes were identified between 
poorly metastatic and highly metastatic cell lines of  rat mammary adenocarcinoma 
R3230AC. Eight cDNA clones from poorly metastatic CAb.D5 cell line and six cDNA 
clones from highly metastatic LN4.D6 cell line were identified (Gunes and Carlsen, 
2003). The aim of this study was to investigate expression profiles of these 
differentially expressed genes in a set of different adenocarcinoma cell lines to find if 
they have any relation with metastasis. Cell culture and stocks of sixteen different cell 
lines were prepared and RNA from these cells were isolated. After synthesizing cDNA, 
RT-PCR analysis was carried out using primers specific for each cDNA clone. It was 
found that the gene clones FF-10 and SG-1 were expressed in non-metastatic cells but 
not in metastatic cells suggesting that they may have a tumor suppressive potential. 
Antioxidants are chemicals that prevents oxidation and free radical damages on 
cells. Because there is some evidence that antioxidants may prevent tumor formation, 
effects of antioxidants such as green tea catechins, beta carotene, lycopene as well as 
zeolite were examined on cancer cell growth and expression profiles of the 
differentially expressed genes. The cells were treated with different amounts of  
antioxidants and the cell growth was determined by MTT assay. The effects of 
antioxidants in gene expression were identified by RT-PCR analysis. At 100µM and 
higher concentrations, epigallocatechingallate (EGCG), epigallocatechin (EGC) and 
beta carotene significantly inhibited cell growth. Lycopene affected the cell growth at 
3µM concentration. FH-2 expression decreased by 1.8-fold with lycopene treatment. In 
addition, EGCG increased the SG-1 expression by 1.14-fold. No effects of antioxidants 
as well as zeolite on the expression of other differentially expressed genes were 
observed. For further studies, investigation of expression profiles of differentially 
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expressed genes in primary and secondary tumors of human will give more definitive 
results for the metastatic relevance of these genes.  
 vi 
ÖZ 
 
Kanser insanlar arasında, kalp hastalıından sonra en sık görülen ölüm 
nedenidir. Kanserlerin çou mutasyonlar nedeniyle oluur. Tümör baskılayıcı genler 
tümör oluumlarınnda belirgin rol oynarlar. Eer bir tümör baskılayıcı gen mutasyona 
urarsa, tümörü oluturan fazla hücre bölünmesine öncülük edebilecek olan hücre 
bölünmesini kontrol etme fonksiyonunu yitirir.Yeni tedavi edici ve önleyici metodlara 
sahip olmak için tumör oluumu ve metastazda etki gösteren genleri saptamak 
önemlidir. 
Bir önceki çalımada, sıçan meme adenokarsinomasında (R3230AC) az 
metastatik ve çok metastatik olan hücre hatları arasında farklı ifade edilen genler 
saptanmıtır. Az metastatik hücre hattı CAb.D5’dan sekiz, çok metastatik hücre hattı 
olan LN4.D6’dan altı klon elde edilmitir (Güne ve Carlsen, 2003). Bu verilere göre, 
bu çalımanın amacı, farklı ifade edilen bu genlerin metastatik ilgileri olup olmadıını 
bulmak için bir seri farklı adenokarsinoma hücre hatlarında ifade edilme profillerini 
aratırmaktır. On altı farklı hücrenin hücre kültürü ve stokları hazırlanmı ve bu 
hücrelerden RNA izole edilmitir. cDNA sentezinden sonra, her cDNA klonu için 
kullanılan özel primerlerle RT-PCR analizi gerçekletirilmitir. Buna göre FF-10 ve 
SG-1 genlerinin tümör baskılayıcı potansiyele sahip olma durumunu iaret eder biçimde 
metastatik olmayan hücrelerde sentezlendii ama metastatik olan hücrelerde 
sentezlenmedii görülmütür.  
Antioksidanlar hücrelerde oksidasyonu ve serbest radikal zararını önleyici 
kimyasal maddelerdir. Antioksidanların tümör oluumunu engelleyebileceini belirten 
bazı kanıtlar nedeniyle, yeil çay, beta karoten, likopen ve bunların yanısıra zeolitin 
kanser hücre büyümesi ve farklı olarak ifade edilmi genlerin ifade edilme profilleri  
üzerine etkileri incelenmitir. Hücreler farklı miktarlarda antioksidanlara maruz 
bırakılmı ve hücre büyümeleri MTT metoduyla izlenmitir. Antioksidanların gen 
ekspresyonu üzerindeki etkileri RT-PCR analizi ile belirlenmitir. Yüz mikromolar ve 
üzeri konsantrasyonlarda epigallokateingalleyt (EGCG), epigallokatein (EGC) ve beta 
karoten belirgin biçimde hücre büyümesini engellemitir. Likopen üç mikromolar 
konsantrasyonda hücre büyümesini etkilemitir. FH-2 geninin ekspresyonu likopen 
etkisiyle 1.8-kat azalmıtır. Ek olarak, EGCG, SG-1 geninin ekspresyonunu 1.14-kat 
arttırmıtır. Ayrıca antioksidanlardan zeolitin farklı ifade edilen genlerin ekspresyonu 
 vii 
üzerine etkisi görülmemitir. Daha ilerki çalımalar için farklı ifade edilmi bu genlerin 
primer ve sekonder insan tümörlerinde eskpresyon profillerinin incelenmesi bu genlerin 
metastatik ilgisi için daha kesin sonuçlar elde etmemizi salayacaktır. 
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CHAPTER 1 
 
INTRODUCTION 
 
Cancer is one of the major health problems in the world. It is the second most 
frequent cause of death in industrialized countries. Men have 44% chance of having 
malignancy, while women have 38% chance of having malignancy at some point during 
their lifetime.  
Cancer is a disease characterized by uncontrolled cell division and invasion of 
these cells to the other tissues where they can be localized. Cancer is caused by genetic 
aberrations activating oncogenes and inactivating tumor suppressor genes. Most of the 
mutations leading to cancer are acquired during the evolution of cancer which is termed 
as tumorigenesis. Some mutations may also be inherited. Furthermore, environmental 
factors play a role in cancer formation. Studying the molecular mechanisms of 
malignancies provide development of new tools for diagnosis, prognosis and treatment 
of cancer (Porkka and Visakorpi 2004). 
Cell proliferation is a normal, physiologic process in which mutations may lead 
to cancer formation changing the order of this process. Tumor suppressor genes have 
role in regulating cell proliferation and cell death. When a mutation occurs in a tumor 
suppressor gene, this change may result in unregulation of cell growth causing tumor 
formation. If the tumor does not spread any other part of the body, it is called benign 
tumor. If it does, then it is called malignant tumor (Rieger 2004). This is why tumor 
suppressor genes have a great importance for exploring new ways in cancer research. 
 
1.1. Tumor and Tumor Formation 
 
        When cells can not be controlled in growth and division, they form a mass 
of tissue which is called tumor. The term tumor originally means “swelling” but this 
term is now primarily used to denote abnormal growth of tissue. Tumors are divided 
into two groups. Benign tumors are tumors that do not spread into other tissues. They 
grow slowly in the originated area and have a good prognosis. This does not mean that 
they can not cause a problem. Benign tumors can cause damage depending on the tissue 
they grow such as brain. The other group of tumors is malignant tumors. Malignant 
tumors are tumors that invade the surrounding tissues and different areas of body. 
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Malignant tumors grow fastly (Artner, 2001). The differences between benign and 
malignant tumors can be summarized as;                                                                   
         Benign vs Malignant 
 Benign cells have limited growth potential while malignant cells proliferate 
rapidly 
 Benign cells are localized, but malignant cells metastasize 
 Benign cells have fibrous capsule, malignant cells have no enclosing capsule  
 Benign cells rarely recur after removal, malignant cells form irregular shape 
with poorly defined borders 
 Benign cells are much different than parent cells (degrees of anaplasia), 
malignant cells are much different than parent cells (degrees of anaplasia) 
(Figure 1.1). 
For malignant cells morphological changes include;  
1. pleomorphism of nuclei and cells  
2. coarsely distributed DNA   
3. increased number of nucleoli  
4. disorderly cell growth (abnormal mitosis) (Porth, 1998) 
 
 
 
 
 
 
 
 
 
Figure 1.1. The upper part of the figure on the left shows the fat-tissue including on the 
left benign Lipoma and on the right malignant Liposarcoma. In Lipoma cells are large 
and it is well-differentiated. The cellular structures are typical for the origin of tissue. 
The capsule at the bottom of the Lipoma can be seen as a sign of non-invading benign 
neoplasm. Liposarcoma shows lack of differentiation. There is no capsule and the cells 
are different from the original tissue in structure. The cells are smaller than the normal 
with varying shapes. The lower part shows the anaplastic carcinoma including variable 
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cellular, nuclear size and shape. The tissue of origin can not be determined (Source: 
Artner 2001).  
Cell proliferation normally takes place in the regulation of cell cycle. It is 
controlled by growth factors binding to receptors on the cell surface. These receptors 
are connected to signaling molecules that convey message from receptor to the nucleus. 
All these regulate the protein formation which cause continous cell division. If any 
mutation occurs in any of the genes encoding these proteins, cell proliferation can not 
be controlled resulting in tumor occurance (King 1996).           
A cancer is formed from a tumor, but a tumor is not always cancerous. Cancer is 
first described for breast carcinoma (Hippocrates) and malignant tumors have been 
found in Egyptian mummies nearly 5000 years old. Ancient medical writings such as 
Edwin Smith and Ebers papyrusses mention about tumors about 3500 years ago. The 
Greek term “karkinos” means cancer and it is described for the abnormal cells. This 
latin description for cancer is first used by Galen (199 a.Chr.). Cancer is now being used 
as malignant growth of cells. (Artner 2001) 
 
1.2. Carcinogenesis and Stages of Tumor Initiation 
 
All cells have a standard growth cycle and physical specifications. When cells 
are effected by carcinogens, changes in their growth cycle and physical specifications 
are seen, which is termed as carcinogenesis. Carcinogenesis have several steps. Damage 
by carcinogenic factors occurs at the beginning of malignant transformation and is 
called initiation. These damage cause changes in proteins, DNA, or signaling pathway. 
The initiation is followed by promotion. Promotion step includes further damage on 
cells in which genome damage can not be repaired. Increase in clonal growth is seen in 
promotion step. Initiation and promotion can be endogenous (genetic mutations) or 
exogenous (chemicals or viral). During carcinogenesis, the normal program including 
differentiation and proliferation of the cell changes. Henceforth, growth, angiogenesis, 
invasion, and metastasis become possible in carcinogenesis step. Progression is the final 
step in carcinogenesis in which a number of cells grow forming a mass called tumor. 
Factors such as immune system response, localization, blood support and the rate of 
growth play an important role in this process. Metastasis is the last stage in which a 
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tumor becomes a cancer. Tumor progression and occurance of metastatic capacity need 
additional changes in gene expression (Artner 2001, Yoshida et al. 2002). 
 
1.3. Cancer and Metastasis 
 
Cancer is a genetic disease mostly arising from accumulation of several 
mutations. Cancer cells over proliferate by their failure of cell cycle control (Griffiths 
2002). These cells continously divide and lead to formation and growth of tumors. 
Another important case for cancer formation is the acquired ability of cancerous cells to 
leave the primary tumor and forming colonies at secondary sites (Lodish 2002). This 
process is known as metastasis and it is caused by the changes of cell to cell adhesion of 
tumor cells (Tepass 2001). These cells find a way to escape from primary tumor and 
travel within the circulatory or lymph system until they attach themselves to a new site 
which is known as secondary site (Lodish 2002). In this secondary site these cells 
invade the tissue by activating various molecules. For example, if breast cancer spreads 
to the lung, the secondary tumor is made up of abnormal breast cancer cells, not 
abnormal lung cancer cells. This means the disease in the lung is the metastatic breast 
cancer, not lung cancer. Usually, carcinomas spread by hematogenous route, and the 
sarcomas spread by lypmhatic route. Adrenal glands, brain, liver and bones are the most 
common parts of the body for metastasis. There are also some types of tumors that only 
seed in particular organs. For example, prostate cancer usually metastases to the bones 
while the stomach cancer mostly metastases to the ovary in women. Cancer cells may 
also spread to regional lymph nodes around the primary tumor site. This is called nodal 
involvement or regional disease (King 1996, Nicolson 1991). 
In metastasis, to be able to leave the original tumor site and migrate to other 
parts of the body, malignant cells attach to extracellular matrix (ECM) by degrading the 
proteins surrounding and separating the tumor from the adjoining tissue. To complete 
the metastatic journey of the tumor cell, this is followed by two events, cell migration 
and angiogenesis (Ahmad and Hart 1997).        
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Cell migration is the movement of cells from one part of the body to another 
(Figure 1.2). Cell migration is properly required for normal organ and structural 
formations. When 
cells fail to migrate or migrate to inappropriate parts, abnormal development is 
observed. Metastasis occurs by the migration of cancer cells from primary tumor site to 
secondary sites where they invade normal tissue causing proliferation and formation of 
new tumors (Tepass 2001).  
 
 
 
 
 
 
 
 
 
 
Figure 1.2. The cells are moving and migrating. (Source: http://cf.unc.edu/our/slides/ 
Weisner04_files/slide0001_image002.jpg) 
 
During cancer research, it is discovered that for tumors to grow beyond 2mm in 
three dimensions, one of the required events is the formation of the new blood vessels 
which is called angiogenesis . Tumor angiogenesis is the proliferation of a new blood 
vessel system to supply oxygen and nutrient intake and removal of waste materials.  
Tumor cells send signals to normal host tissue and these signals activate the 
genes related to growth of blood vessels. Such new blood vessels for tumor cells are 
thin-walled so that tumor cells can easily exit the primary site to metastasize. The 
angiogenesis consists of stages which are 1) dissolution of the basement membrane, 2) 
endothelial cell migration, 3) endothelial cell proliferation, 4) vascular loop formation 
and 5) development of new basal membrane (Ahmad and Hart 1997, Hanahan and 
Weinberg 2000). 
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         Shortly,  the metastatic cascade can be figured as; 
 
 
Initial transforming event 
 
 
Growth of neoplastic cells 
 
 
Neovascularization/angiogenesis of the tumor 
 
 
Detachment of neoplastic cells from primary tumor 
 
 
Local invasion of extracellular matrix by tumor cells 
 
 
Intravasation of tumor cells into lymphatics or vasculature 
 
 
Survival of tumor cells in circulation and avoidance of immunological attack 
 
 
Extravasation of tumor cells from vasculature into secondary organ tissue 
 
 
Survival and proliferation within organ parenchyma 
 
Figure 1.3. The metastatic cascade (Ahmad and Hart 1997). 
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Figure 1.4. Stages of metastasis beginning from primary tumor, spreading via blood and 
lymph system and formation of new tumors in the secondary site (Source: 
http://207.68.36.7/ths/ science/apbio/ch5-8.gif). 
           
Finally, for a successful metastasis each step required for production of 
metastases must be completed (Figure 1.4). If one step fails, the metastasis can not be 
completed. 
 
1.4. Factors Causing Cancer 
 
Cancer is not the result of  a single effect, multiple changes can lead to cancer. 
There are many different factors causing cancer such as hereditary factors, viral factors, 
radiation, chemical factors, immune system factors, environmental factors, life style and 
dietary factors (Artner 2001). 
Several mutations are needed for a cell to become cancerous. These mutations 
involve oncogenes and tumor suppressor genes. Mutations may have different causes. 
Some of them belongs to the specific cancer cases. Smoking is related with lung cancer, 
exposure to radiation or ultraviolet radiation from sun is associated with skin cancer 
(melanoma). Chemicals and free radicals also cause mutations and form cancer. 
Mutations can also be inherited such as BRCA1 gene which is a factor in developing 
breast and ovarian cancer. Some types of viruses also cause mutations. Herpesviruses, 
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Papillomaviruses, and retroviruses are called as oncoviruses carrying oncogenes and 
tumor suppressor inactivating genes in their genomes (Rieger 2004, Artner 2001).  
It is not possible to define the initial cause for any specific cancer. By the 
developing molecular biology techniques, it is possible to charactarize the mutations in 
a tumor. For example, tumor suppressor gene p53 is known as “the guardian of the 
genome” because of its potential, when mutated, to cause formation of most tumors.  
 
1.5. Tumor Suppressor Genes 
 
Tumor suppressor genes are genes whose loss of function may lead to malignancy 
(Osborne et al. 2004). Tumor suppressor genes are normally found in our cells. They 
function in regulating diverse cellular activities such as cell cycle checkpoint responses, 
detection and repair of DNA damage, protein ubiquitination and degradation, mitogenic 
signaling, cell differentiation and migration and tumor angiogenesis. Over the last 15 years 
many tumor suppressor genes have been identified (Sherr 2004). When a mutation occurs in 
a tumor suppressor gene, this may result in tumor formation or growth. A mutation in a 
tumor suppressor gene is like an automobile with a dysfunctional brake, the car does not 
stop even the driver attempts to stop it (Vogelstein and Kinzler 2004).  
The first experiments about the activity of tumor suppressor genes were done 
including somatic cell hybridization experiments by Henry Harris and his colleagues in 
1969 (Cooper 2000). Isolation of tumor suppressor genes in the late 1980s and 1990s 
has improved the studies on genetic alterations in human cancer cells (Yokota 2000). 
Retinablastoma (Rb) was the first identified tumor suppressor gene in 1986 (Friend et 
al. 1986). Later on, more than 20 tumor suppressor genes have been identified to date 
(Haber and Harlow 1997, Fearon et al. 1997). The second identified tumor suppressor 
gene was p53 which is now very popular in cancer research. Inactivated p53 is very 
common among most of the mutations taking role in tumor initiation. This makes p53 
the most common target for genetic alterations in human cancers (Cooper 2000). 
Tumor suppressor genes are mostly recessive at the cellular level because they 
need to be mutated for both copies of the gene pairs to be able to cause malignancy. 
Mutations in tumor suppressor genes mostly occur as the result of aging and/or 
environmental factors. A mutation of a tumor suppressor gene can be inherited from a 
parent. When a mutation in the second copy occurs the process of tumor formation 
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begins. This is also called “two-hit theory” (Knudson 1971). “Two-hit” hypothesis 
states that tumor suppressor genes are inactivated following a recessive mutation in one 
allele and the loss of other wild-type allele (Weir et al. 2004). The genes related with 
hereditary cancer are mostly tumor suppressor genes.  
Identification of tumor suppressor genes are more difficult than oncogenes. They 
are important for marker development as their loss may be related with the metastatic 
potential. They also provide new aspects for therapeutic targets. The studies done about 
the mechanisms of loss of metastatic suppressor gene expression suggest that metastatic 
suppressor genes are not mutated but are differentially expressed (Steeg et al. 2003). 
 
Table 1.1 (cont.). Selected Tumor Suppressor Genes and Associated Protein Function 
(Table modified from Table 1 of Fearon ER. Tumor suppressor genes. In: Vogelstein B, 
Kinzler KW, eds. The Genetic Basis of Human Cancer, 2nd Edition. McGraw-Hill: New 
York, NY. In press.) 
Gene Associated inherited 
cancer syndrome 
Cancers with somatic 
mutations 
Presumed function of 
protein 
 
RB1 Familial retinoblastoma Retinoblastoma, 
osteosarcoma, 
SCLC, breast, 
prostate, bladder, 
pancreas, 
esophageal, others 
Transcriptional 
regulator; E2F binding 
TP53 Li-Fraumeni syndrome Approx. 50% of all 
cancers (rare in some 
types, such as 
prostate carcinoma 
and neuroblastoma) 
Transcription factor; 
regulates cell cycle and 
apoptosis 
 
 
INK4a     
p16 Familial melanoma, 
Familial pancreatic 
carcinoma 
Approx. 25-30% of 
many different 
cancer types (e.g., 
breast, lung, 
pancreatic, bladder) 
Cyclin-dependent 
kinase inhibitor (i.e., 
Cdk4 and Cdk6) 
p19ARF  ?Familial melanoma? Approx. 15% of 
many different 
cancer types 
Regulates Mdm-2 
protein stability and 
hence p53 stability; 
alternative reading 
frame of p16/INK4a 
gene 
   (cont.on next page) 
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APC Familial adenomatous 
polyposis coli (FAP), 
Gardner syndrome, 
Turcot's syndrome 
Colorectal, desmoid 
tumors 
Regulates levels of β-
catenin protein in the 
cytosol; binding to 
microtubules 
BRCA1 Inherited breast and 
ovarian cancer 
Ovarian (~10%), rare 
in breast cancer 
DNA repair; 
complexes with Rad 51 
and BRCA2; 
transcriptional 
regulation 
BRCA2 Inherited breast (both 
female and male), 
pancreatic cancer, 
?others? 
Rare mutations in 
pancreatic, ?others/ 
DNA repair; 
complexes with Rad 51 
and BRCA1 
WT-1 WAGR, Denys-Drash 
Syndrome 
Wilms' tumor Transcription factor 
NF-1 Neurofibromatosis type 
1 
Melanoma, 
neuroblastoma 
p21ras-GTPase 
NF-2 Neurofibromatosis type 
2 
Schwannoma, 
meningioma, 
ependymoma 
Juxtamembrane link to 
cytoskeleton 
VHL von-Hippel Lindau 
syndrome 
Renal (clear cell type), 
hemangioblastoma 
Regulator of protein 
stability 
MEN-1 Multiple endocrine 
neoplasia type 1 
Parathyroid adenoma, 
pituitary adenoma, 
Endocrine tumors of 
the pancreas 
Not known 
PTCH Gorlin syndrome, 
hereditary basal cell 
carcinoma syndrome 
Basal cell skin 
carcinoma, 
medulloblastoma 
Transmembrane 
receptor for sonic 
hedgehog factor; 
negative regulator of 
smoothened protein 
PTEN/MMAC1  Cowden's syndrome; 
sporadic cases of 
juvenile polyposis 
syndrome 
Glioma, breast, 
prostate, follicular 
thyroid carcinoma, 
head and neck 
squamous carcinoma 
Phosphoinositide 3-
phosphatase; protein 
tyrosine phosphatase 
DPC4 Familial juvenile 
polyposis syndrome 
Pancreatic(~50%), 
approx. 10 15% of 
colorectal cancers, 
rare in others 
Transcriptional factor 
in TGF-β signaling 
pathway 
 
E-CAD Familial diffuse-type 
gastric cancer; Lobular 
breast cancer 
Gastric (diffuse 
type), lobular breast 
carcinoma, rare in 
other types (e.g., 
ovarian) 
 
Cell-cell adhesion 
molecule 
   (cont.on next page) 
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LKB1/STK1  Peutz-Jeghers syndrome Rare in colorectal, 
not known in others 
Serine/threonine 
protein kinase 
SNF5/INI1  Rhabdoid predisposition 
syndrome (renal; or 
extra-renal malignant 
rhabdoid tumors), 
choroid plexus 
carcinoma 
medulloblastoma; 
central primitive 
neuroectodermal 
tumors) 
Rare in rhabdoid 
tumors, choroid 
plexus carcinoma, 
medulloblastoma 
Member of the 
SWI/SNF chromatin 
ATP-dependent 
remodeling complex 
EXT1 Hereditary multiple 
exostoses 
Not known Glycosyltransferase; 
heparan sulfate chain 
elongation 
EXT2 Hereditary multiple 
exostoses 
Not known Glycosyltransferase; 
heparan sulfate chain 
elongation 
TSC1 Tuberous sclerosis Not known Not known; 
cytoplasmic vesicle 
localization 
TSC2 Tuberous sclerosis Not known Putative GTPase 
activating protein for 
Rap1 and rab5; golgi 
localization 
MSH2, MLH1 
PMS1, PMS2, 
MSH6  
Hereditary non-
polyposis colorectal 
cancer 
Colorectal, gastric, 
endometrial 
DNA mismatch repair 
 
 
1.6. Cancer Research and Model Organisms 
 
Metastasis is the most lethal stage of a cancer. The gene expression analysis of 
known tumor suppressors and oncogenes provide an understanding approach of context 
of early tumorigenesis and role of these genes in cancer formation (Hahn and Weinberg. 
2002). Developments in complete sequencing of human genome have provided an 
acceleration in discovery of cancer-related genes and pathways (Baak et al. 2003). 
Some organisms have metabolic events similar to the events in humans. These 
organisms led scientists create models helping to understand processes that take place in 
and cause cancer. Model organisms including Drosophila melanogaster and the mouse 
have been used to perform experiments to study genetic alterations leading to cancer 
(Griffith 2002). The experiments done by Chakraborty and Yamaga (2003) provided 
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information  about regulation of metastasis by exploring the effects of in vitro fusion of 
poorly metastatic melanoma cells with macrophages from mice which produced hybrids 
with metastatic potentials. Tumor formation and development in Drosophila constitutes 
another model for understanding cancer mechanisms. Especially, it is used in genetic 
techniques allowing rapid identification and characterization of related genes (Potter 
2000).  
The search for metastasis-suppressor genes was first initiated in the late 1980s 
(Yoshida et al. 2000). Identifying these genes are important as they have a functional 
role in the acquisition of metastatic ability. This research needs well-characterized in 
vivo (animal) models completed with experimental studies. However, in vitro models 
do not directly reflect in vivo metastasis (Welch D.R. 1997). As the metastasis is a 
complex and multigenic phenotype, several markers are needed to distinguish metastatic 
ability of tumor cells. Observing tumor cell growth at metastatic level is an important 
clinical target since inhibition of such growth requires identification of genes or proteins 
regulating metastatic colonization (Yoshida et al. 2000). Thus, gene expression profiling 
especially detected by sensitive methods such as RT-PCR (Reverse Transcriptase 
Polymerase Chain Reaction) has become an issue of interest (Gomella et al. 1997).  
Finally, the identification of genes and pathways involving tumor growth and 
metastasis will provide us both understanding of the cancer biology and will give new 
targets for early detection and treatment of cancer. Gene expression profiling has also 
provided information for tumor subclassification (Garnis et al. 2004). Additionally, 
working with model organisms will hopefully provide answers to many questions in 
terms of the molecular mechanisms of metastasis. 
 
1.7. Antioxidants 
         
Several anticarcinogens and antimutagens have the ability to inhibit propagation 
of peroxidation processes by peroxy radicals which is called as antioxidant property 
(Pziezak 1986). Peroxy products (H2O2, ROOH) and different oxygen radicals (-OH, -
O2, ROO-, ARO-) have an important role in carcinogenesis (Chiu et al. 1982). 
According to many studies, it is suggested that dietary antioxidants are critical in cancer 
prevention and research on this area is gaining interest (Cutler 1984).  
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An antioxidant is a chemical which prevents oxidation of other chemicals. In 
biological systems, during oxidation, highly reactive free radicals are produced. These 
free radicals may damage the other molecules in the body by reacting with them. The 
research on antioxidant function in cancer treatment is a rapidly evolving area. They 
have been comprehensively studied for their ability to prevent cancer (Singh and 
Lippman 1998). 
In many studies, it was suggested that antioxidants may interfere with alkylating 
agents (Labriola and Livingston 1999). Antioxidants have been put forward to increase 
cell death (apoptosis) by this mechanism (Chinery et al. 1997, Mediavilla et al. 1999). 
Several animal studies have been published showing decreased tumor size and/or 
increased longevity with the combination of chemotherapy and antioxidants (Seifter et 
al. 1984, Berry et al. 1984). 
        Many chemicals, such as retinol (vitamin A or beta-carotene), ascorbic acid 
(vitamin C), vitamin E (tocopherol), selenium, melatonin, coenzyme Q10, n-
acetylcysteine, glutathione, and flavanoids have been used as antioxidants for cancer 
treatment and prevention studies (Halliwell 1999). 
 
1.8. Green Tea Catechins 
 
There is increasing evidence that specific substances found in certain foods such 
as phenolic compounds found in plants. Flavanoids are powerful antioxidants in vitro 
and they are found in tea. They have been identified as cancer preventing components 
(Middleton et al. 1994, Smith et al. 2001, Lynn-Cook et al. 1999). Tea has been shown 
to inhibit tumorigenesis at the initiation, promotion and progression stages of cancer. 
Their mechanisms have been suggested as including; 1) antioxidant activity, 2) ability 
to inhibit nitrosamine reactions, 3) modulation of carcinogen-metabolising enzymes, 4) 
ability to inhibit cell proliferation (Dreosti et al. 1997). Some studies have shown that 
there is an inverse association between green tea drinking and stomach cancer 
(Bushman 1998, Setiawan et al. 2001). 
There are mainly three types of tea that are green tea, black tea and oolong tea-
differing in chemistry and how they are produced. A typical green tea beverage contains 
30-42%  catechins by dry weight. These catechins are (-)-epigallocatechin (EC), (-)-
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epicatechin-3-gallate (ECG), (-)-epigallocatechin (EGC), (-)-epigallocatechin-3-gallate 
(EGCG).  
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
Figure 2.1. Structure of green tea polyphenols (Lin and Liang, 2000). 
The effects of EGCG and the other polyphenols on cancer prevention may be the 
result of decreased cell transformation and proliferation or increased apoptosis. In many 
studies, in vitro, tea catechins, especially EGCG have been shown to cause inhibition in 
growth of various human tumor cell lines including melanoma, lung cancer, breast 
cancer, leukemia, and colon cancer (Chung et al. 2001, Yang et al. 1998).  
 
1.9. Beta Carotene 
 
Carotenoids are naturally occuring pigments synthesized by plants and 
microorganisms, but not by animals. Beta carotene is a group of carotenoids which has 
two cyclo hexene type end groups (Goodwin 1980). 
By the early 1980s large number of epidemiological studies have shown that 
beta carotene can prevent cancer (Willett et. al 1984). Several studies have shown that 
beta carotene and other carotenoids have lipid-soluble antioxidant activity. Beta 
carotene is studied mostly in homogenous lipid solutions, in membrane models and in 
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intact cells resulting as a less effective antioxidant than -tocopherol (Woodall et al. 
1997). In recent studies, increase in lung cancer cells after treatment with beta carotene 
suggested that beta carotene might possess co-carcinogenic potential. Epidemiological 
and experimental observations have indicated that fruits and vegetables rich in 
carotenoids may have a role in cancer treatment and prevention (Paolini et al. 2003). 
Beta carotene is scavenger of peroxyl radicals at low oxygen tension (Burton 
and Ingold 1984). The antioxidant actions of beta carotene are based on its ability to 
bind peroxyl radicals. 
 
1.10. Lycopene 
 
Lycopene is a natural pigment and it is only synthesized by plants and 
microorganisms. It is a carotenoid and an acyclic isomer of beta carotene. Recent 
studies on lycopene has focused on its antioxidant properties (Rao and Agarwal 2000). 
Lycopene has been shown as an inhibitor on the growth of human endometrial, 
mammary and lung cancer cells and it was reported as more effective than  or  
carotene (Levy et al. 1995). Epidemiological studies on the role of lycopene in relation 
to chronic diseases have focused primarily on cancers (Rao and Agarwal 2000). Some 
scientists have reported inverse association of lycopene with breast cancer risk 
(Potischman et al. 1990, Zhang et al. 1997). 
 
1.11. Zeolites 
 
Zeolite is a popular and important group of minerals for industrial and other 
purposes. Zeolite is crystalline aluminosilicate with fully cross-linked open framework 
structure made up of corner sharing SiO4 and AlO4 tetrahedra. The name “zeolite” 
comes from the Greek words zeo (to boil) and lithos (stone). It was named by Swede 
minerologist Fredrich Cronstdet who explored the mineral in 1756. 
The main structure of a zeolite is constituted by SiO4 and/or AlO4. Most 
significant features of this structure are pores and cavities providing ability to release 
water in these pores and cavities at high temperatures without losing its original form; 
and possessing loosely bounded, exchangeable cations. Therefore  it can successfully be 
used in adsorption, ion exchange and dehydration processes. More than 40 natural and 
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more than 150 artifical types of zeolites are being used today in fields such as 
agriculture and stockbreeding, pollution control, energy applications, and mining and 
metallurgy (Breck 1974, Tsitsishvili et al. 1992).  
Clinoptilolite is a type of natural zeolite which is most abundant in nature. In 
clinoptilolite, changes can be seen in the composition of framework and exchangeable 
cations such as K+,, Na+, Ca2+. Clinoptilolite can also be used for adsorption processes 
and ion exchange separations like other types of natural zeolites (Ackley et al. 1992). 
Clinoptilolite has been also suggested that it may show diverse biological activities. It 
has been reported as a potential supportive agent for anticancer therapy (Paveli et al. 
2001). 
 
1.12. Thesis Objectives 
 
Identification of differentially expressed tumor genes have an important place in 
cancer research to get a better understanding the mechanisms of malignancy and to 
develop markers. In a previous study, there were differentially expressed genes between 
poorly metastatic CAb.D5 and highly metastatic LN4.D6 cell lines of rat mammary 
adenocarcinoma R3230AC. In CAb.D5 8 cDNA clones (FA-8: rat alpha 2 collagen IV; 
FC-1: rat aldehyde dehydrogenase; FC-6: rat proalpha 1 collagen III; FC-7: ribosomal 
protein L4; FF-10: osteoblast/osteocyte Factor 45; FH-2: rat cytokeratin 8; SG-1) and in 
LN4.D6 6 cDNA clones (RB-8: neutrophil chemoattractant 2; RB-9: human LGN 
protein; RD-4: mouse aspartylaminopeptidase; RE-1: rat keratin (C K5) mRNA; RF-5: 
mouse keratin (epidermal) type 1) were identified (Gunes and Carlsen 2003).Based on 
the previous findings, the objectives of this study were; 
 investigating the expression profiles of differentially expressed genes in 
various (16) adenocarcinoma and tumor cell lines by reverse transcriptase polymerase 
chain reaction (RT-PCR) in order to see the metastatic relevance of these genes 
 investigating the effects of antioxidant compounds like green tea catechins, 
beta carotene, lycopene as well as a silica mineral zeolite on the growth of tumor cell 
lines and expression profiles of  differentially expressed genes. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1. Materials 
 
Cell lines were kindly supplied from some colleagues as listed below. For cell 
culture experiments, Roswell Park Memorial Institute (RPMI)-1640 medium and 
Trypsin were purchased both from Sigma Chemical Company and Biological Industries 
Chemical Co. Fetal Bovine Serum (FBS),  trypan blue, gel loading solution, MTT, 
sodium bicarbonate, Green tea catechin (GTC), Epigallocatechin gallate (EGCG),  
carotene, Epigallocatechin (EGC), Lycopene, phenol were purchased from Sigma 
Chemical Company. DMSO, sodium citrate, sodium chloride were purchased from 
Merck Chemical Co. Fetal Calf Serum (FCS) was purchased from Biological Industries 
Ltd. Penicilin Streptomycine was purchased from Biochrom Chemical Co. Ethidium 
Bromide, 2-Mercaptoethanol, EDTA (Disodium Salt Dihydrate), sodium phosphate 
(monobasic and dibasic) were purchased from Amresco Chemical Co. DEPC was 
obtained from Serva Chemical Co. Tetrahydrofurane (THF) was purchased from 
Lachema Co. Zeolites were kindly supplied by Prof. Dr. Semra Ülkü, Chemical 
Engineering Deparment of Izmir Institute of Technology. Tissue culture plates were 
from Corning Star, and polypropylene tubes and disposable pipettes were obtained from 
Greiner. 
For RNA isolation, Nucleospin® RNA II Kit and for cDNA synthesis by RT-
PCR,  Advantage™ RT-for-PCR Kit  were purchased from BD Biosciences, Clontech. 
 
2.2. Methods 
 
2.2.1. Preparation of Cell Lines 
 
There were sixteen different cell lines used for this project. Rat mammary 
adenocarcinoma cell lines CAb.D5, LN4.D6, 13762 CT, 13762 WT and rat prostate 
adenocarcinoma cell lines. AT-1 and MATLyLu were supplied by Dr. S.Carlsen, 
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Saskatchewan Cancer Agency, Canada. Rat prostate adenocarcinoma cell lines AT-2, 
AT-3 and MATLu were supplied by Dr. J.A.Schalken, University Medical Center, 
Experimental Urology, Nijmegen, Netherlands. Human mammary adenocarcinoma cell 
lines MCF-7, HBL-100, MDA-MB-453, T-47-D were supplied by Dr. M. Öztürk, 
Bilkent University. Human prostate adenocarcinoma cell lines LNCAP,  PC-3 were 
supplied by Dr. Ahmet anlıolu, Akdeniz University and DU145 was supplied by 
GATA. Human cervix adenocarcinoma cell line HeLa and human colon 
adenocarcinoma cell line CAC0-2 were supplied by Dr. I. Gürhan, from Ebiltem, Ege 
University. 
When the cell lines arrived at the laboratory, they were incubated for 2-4 hours 
in a CO2 incubator at 37 ˚C in a humidified atmosphere. At the end of incubation period 
plaque of the flask was opened carefully and entrance of the flask was swapped with 
ethanol. Then culture medium was poured slowly in another vessel until 10-15 ml 
remained. The entrance of the flask was swapped again with ethanol and incubated 
overnight in a CO2 incubator at 37 ˚C in a humidified atmosphere. Approximately 20 
hours later cells were prepared for trypsinization. 
For trypsinization the medium was removed from the flask and phosphate 
buffered saline (PBS) at pH: 7.4 was added to wash and get rid of unwanted proteins in 
the medium. After washing, trypsin was added to cover the surface of the cells and 
waited for 15-30 seconds. Trypsin was decanted until a few drops remained and 
incubated for 2-5 minutes depending on the cell line. At the end of the incubation, 10 ml 
medium (RPMI 1640 supplemented with 8% FCS, 100 µg/ml streptomycine, and 100 
u/ml peniciline, pH: 7.1) was added by pipetting to disperse the adhesive tumor cells. 
The cell suspension was transferred into 15 ml falcon tube and centrifuged at 800 rpm 
twice (for 6 minutes). After removing the supernatant, cells were washed twice and the 
cells resuspended in the medium. Then cells were dissolved with 3 ml RPMI 1640 by 
pipetting up and down and 1 ml cell suspension was put into eppendorf tube to count 
the cells . After that, cell count was performed by using a hemacytometer. The viability 
of the cells was determined by the trypan blue exclusion method. The total number of 
cells was calculated based on the formula below. 
            Number of cells/ml= Number of cells counted in 25 square x Dilution factorx104 
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2.2.2. RNA Isolation 
 
RNA isolation was carried out using Nucleospin® RNA II Kit (BD Biosciences, 
Clontech). 
The cells (1x106) were put into 1.5 ml eppendorf tube and centrifuged at 8000 
rpm (for 30 sec).  In the tube, 350 µl RA1 solution and 3.5 µl -ME were added and 
mixed by vortexing. In order to clean the cell lysate, the mixture was passed through the 
Nucleospin filter column by spinning at 11000 rpm for 1 min. 350 µl of 70% ethanol 
was added into the lysate and mixed by vortexing. A Nucleospin column was put into a 
2 ml collection tube and the sample was loaded into the column. The tube was 
centrifuged at 8000 rpm for 30 sec. The flowthrough was discarded. Then 350 µl of 
Buffer MDB was added and centrifuged at 11000 rpm for 1 min. The flowthrough was 
discarded at the end of the centrfiugation. DNAse I mixture reconstituted before and 95 
µl of DNAse I was added to the Nucleospin column and incubated at room temperature 
for 15 min. After incubation, 200 µl of Buffer RA2 was added and centrifuged at 8000 
rpm for 30 sec. The 2 ml Nucleospin column was changed by a new one after the 
flowthrough was discarded. Then 600 µl of Buffer RA3 was added and the tube was 
centrifuged at 8000 rpm for 30 sec. The tube was placed into the column after the 
flowthrough was discarded. Again, 250 µl of Buffer RA3 was added and this time tube 
was centrifuged at 11000 rpm for 2 min. When the flowthrough was discarded the 
column was placed into 1.5 ml microcentrifuge tube. After that, RNA was eluted by 
adding 60 µl of DNAse free water and centrifuged at 11000 rpm for 1 min. The RNA 
isolated was quantified by UV spectroscopy. The RNA samples were stored at -80˚C 
until used. 
 
2.2.3. Quantification of RNA 
 
The quantity and quality of the RNA samples were determined by analysis of 
absorption profiles at 260 nm and 280 nm. If the ratio of absorption at 260 nm/280 nm 
was 1.8+0.01, the samples considered as pure RNA (Maniatis et al. 1982). 
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2.2.4. RT-PCR (Reverse Transcriptase Polymerase Chain Reaction) 
Analysis 
 
Reverse transcriptase polymerase chain reaction is the technique that provides 
the transcription of an RNA strand into a DNA complement using reverse transcriptase 
enzyme. The complementary DNA is then amplified by Polymerase Chain Reaction 
(PCR). In this study, cDNA synthesis was achieved by the protocol in Advantage™ RT-
for-PCR Kit (BD Biosciences, Clontech). All dilutions and additions were carried out 
on ice and all the reagents were spinned before usage. In a sterile 0.5 ml 
microcentrifuge tube, 12.5 µl of RNA sample including DEPC- treated water was 
added. According to the amount of RNA sample, 1 µl of random hexamer or the oligo 
(dt) primer was added. The RNA was heated at 70 ˚C for 2 min and then put on ice 
rapidly. A master mix including 4 µl of 5x Reaction Buffer, 1 µl dNTP mix (10 mM 
each), 0.5 µl Recombinant RNAse Inhibitor, and 1  MMLV Reverse Transcriptase for 
each RNA sample was prepared. Then 6.5 µl of master mix was added to each tube. The 
contents of the tube was mixed by pipetting up and down and incubated at 42 ˚C for 1 
hr. After incubation, the tube was heated at 94 ˚C for 5 min to stop cDNA synthesis and 
to destroy DNAse activity. After the tube was spinned down, the reaction was diluted to 
a final volume of 100 µl by adding 80 µl of DEPC-treated water. Finally that mixture 
was vortexed and spinned again. The cDNA sample was stored at -80 ˚C until used. In 
each PCR reaction 2 µl of cDNA sample was used. 
 
2.2.5. Polymerase Chain Reaction (PCR) 
 
PCR is used to amplify DNA with primer pairs specific for each cDNA clone. 
All PCR reactions were carried out in 50 µl reaction volumes. In the PCR mixture 2 µl 
cDNA was mixed with 0.2 mM dNTP  3 Mm MgCl2, 1x PCR buffer, 2U Taq 
Polymerase and 1 µM of each primer. Amplifications were carried out in a DNA 
thermal cycler (Techne Progen). The initial denaturation was at 94 ˚C for 2 minutes and 
the final extension was at 72 ˚C for 10 minutes for all the primer pairs. Thirty-five 
cycles were applied, and the annealing temperatures was 54 ˚C. 
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The PCR products were electrophorased on 1.5% agarose-ethidium bromide gel 
in TAE buffer (0.04 M Tris-Acetate, 0.001 M EDTA; pH:8.0) at 90 V for 40 minutes. 
Gels were visualized in a gel documentation system (Vilber Lourmat, France). 
 
2.2.6. Determination of Cell Growth by MTT Assay 
 
Green Tea Catechins including Epigallocatechin gallate (EGCG), 
Epigallocatechin (EGC), Green tea catechin (GTC); Lycopene and  carotene were used 
as antioxidants to see the effect of them on cell growth and gene expression profiles.  
The in vitro tetrazolium-based colorimetric assay was used to measure cell 
growth after treatment with antioxidants.  This method includes the formation of purple 
water insoluble formazan crystals from yellow water-soluble substrate 3-(4,5 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide by the effect of mitochondrial 
enzymes of metabolically active cells.  
The cell lines were grown until they reach 90% confluency. After trypsinization, 
the cells were plated in 96 wellplate at a concentration of 2x104 cell/well as duplicate. 
Then they were incubated at 37 ˚C for 1 day in humidified 5% CO2 incubator. 
The green tea catechins were prepared in DMSO getting the final concentrations 
as 1µM, 10µM, 50µM, 100µM and 200µM. After incubating the cells for 1 day, 4µl of 
each dilution was added into the wells. They were incubated at 37˚C for 3 days in 5% 
CO2 incubator. After incubation, the medium was removed and 200µl fresh medium 
was added. Then 20µl MTT (5mg/ml in PBS) was added and left for incubation at 37˚C 
for 4 hrs in 5% CO2 incubator. Into each well 200µl DMSO was added and they were 
incubated  for 5 min at room temperature on orbital shaker at 150rpm. Finally the 
absorbance of each well was read by 540nm microplate reader. 
Lycopene was dissolved in 5% tetrahydrofurane (THF). Effects of lycopene at 3, 
6, 9,and 18 micromole on cell growth was determined with MTT assay. 
Zeolites at 0.5mg/ml, 5mg/ml, 10mg/ml, and 20mg/ml were dissolved in RPMI 
1640 medium by shaking on orbital shaker at 220rpm overnight at room temperature. 
Next day, each sample was centrifuged to remove the zeolite particles and supernatant 
was used to treat the cells. Cells were plated at 2.5x104 cells/well in 96 wellplates. Cells 
were allowed to grow at 37˚C in humidified 5% CO2 incubator overnight. Medium was 
removed and 200µl supernatant obtained from zeolite solution at different concentration 
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was added to each well. Cells were allowed to grow 48 hrs. After removing the 
medium, fresh medium was added into wells. Then, 20µl MTT solution (5mg/ml in 
PBS) was added and incubation was carried out for 4 hrs at 37˚C in humidified 5% CO2 
incubator. The formazan crystals formed were dissolved by addition of 200µl DMSO 
into each well. Optical density of color formation in each well was measured at 570nm 
on a microplate reader after 10 min incubation. 
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Figure 2.1. X-Ray diffraction pattern of natural zeolite 
 
According to the X-ray diffraction pattern the zeolite used in this study was 
found as clinoptilolite rich natural zeolite.  
The clinoptilolite content of natural zeolitic mineral was calculated by using 
Relative Intensity Ratio (RIR) methods. This method has been measured for one or 
more reflection and can be defined as the intensity of o peak of interest for a given 
phase divided by the intensity of a peak from a standard (50:50 mixture) (Bish and 
Chipera, 1995). The content of clinoptilolite was found aroun 80 %. Further study 
(chemical and thermal) is required for the identification of the mineral used. 
 
 
2.2.7. Quantification of Gene Expression Level with RT-PCR 
 
Cells were treated with antioxidants and zeolite as it was explained in cell 
growth (3.3). These reagents were EGCG, EGC, GTC, and beta carotene at 100µM, 
lycopene at 9µM and zeolite at 0.5mg/ml, 5mg/ml, 10mg/ml, and 20mg/ml 
concentrations. RNA was isolated from cells treated with each of these antioxidants. 
After synthesis of cDNA, each differentially expressed gene was amplified with a 
specific primer pair by PCR. PCR products were resolved in 1.5% agarose-ethidium 
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bromide gel. Intensity of DNA bands in the gel was quantified by gel documentation 
system (Vilber Lourmat, France) and the level of mRNA for each gene was normalized 
to the level of the GAPDH, internal standard. 
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CHAPTER 3 
 
RESULTS AND DISCUSSION 
 
3.1. Expression Profiles of Differentially Expressed Genes in Different 
Cell Lines 
 
 
The expression profiles of previously described genes of rat mammary 
adenocarcinoma cells were investigated in various tumor cell lines by using RT-PCR. 
cDNA at different concentrations for each reaction were used for PCR. There was a 
linear relationship between log of the signal  (amplified cDNA product) and log of the 
cDNA input (data not shown). Therefore, cDNA concentrations was chosen at a 
concentration in which there was a linear increase in the PCR product for each gene. 
The results of expression patterns of each differentially expressed gene are given below: 
 
FA-8: (Rat alpha 2 collagen IV): When the expression level of the FA-8 
clone was examined in a set of metastatic and non-metastatic rat tumor cell lines, it was 
expressed in non-metastatic CAb.D5 and AT-1 cells. However, no expression was 
observed in other non-metastatic cell lines (Figure 3.1.A).  
There was no singificant expression of FA-8 in metastatic LN4.D6 cell line. As 
it was highly expressed in CAb.D5 cells and not expressed in LN4.D6 cells, FA-8 has 
been suggested to have a relationship with low metastatic potential of CAb.D5 cells 
(Gunes and Carlsen 2003). Even though there was almost no expression of FA-8 in 
LN4.D6 cells, it was expressed in other metastatic cells (Figure 3.1.A). This result 
suggests that FA-8 may not be related with non-metastatic potential of the cell.  
 
FC-1: (Rat aldehyde dehydrogenase): Expression pattern of FC-1 clone 
did not correlate with the metastatic status of the cell because it was expressed in both 
metastatic and non-metastatic cell lines (Figure 3.1.B). In addition, no expression was 
observed in 13762 CT and AT-2 non-metastatic rat cell lines. Even though FC-1 
expression was less than that of non-metastatic CAb.D5 cell. The expression level of 
FC-1 was 4-fold, 1.3-fold, and 2-fold less in metastatic cells LN4.D6, MATLu, 
MATLyLu respectively compared to non-metastatic cell line CAb.D5 (Table 3.2). 
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Because FC-1 was not expressed in other non-metastatic cell lines 13762 CT 
and AT-2, it may be suggested that FC-1 does not have metastatic suppression potential. 
 
FC-6: (Rat pro-alpha 1 collagen III): According to the expression level 
of FC-6 clone in the cell lines, it was significantly expressed in non-metastatic CAb.D5 
cells (Figure 3.1.C). In non-metastatic cell lines 13762 CT and AT-2 and metastatic cell 
line AT-3, there was no expression of FC-6. There were 3.2-fold, 4.2-fold, 5-fold and 
2.4-fold expression levels of FC-6 clone in metastatic LN4.D6, MATLu, MATLyLu 
and non-metastatic AT-1 cells orderly (Figure 3.2).  
An important step in metastatic cascade is the invasion of the extracellular 
matrix by tumor cells (Ahmad and Hart 1997). Extracellular matrix is made up of 
basement membrane and interstitial connective tissue. Collagen fibers are main 
components of interstitial connective tissue which functions as a barrier for tumor cell 
invasion. Therefore, a decrease in collagen fibers in LN4.D6 cells may be responsible 
for the cells to become metastatic. 
However, comparison of the expression level of FC-6 clone in metastatic and 
non-metastatic cell lines (Figure 3.1.C) indicates that rat pro-alpha 1 collagen III is not a 
reason for the cells to become non-metastatic because no expression was observed in 
non-metastatic AT-2 and 13762 CT cells. 
FF-10: (Osteoblast/osteocyte factor 45): FF-10 clone was highly 
expressed in non-metastatic CAb.D5 and AT-1 cells (Figure 3.1.D). Besides, there was 
no expression of FF-10 in other metastatic and non-metastatic cell lines.  
Previously, FF-10 was described as osteoblast/osteocyte factor 45 (Petersen et 
al. 2000). These researchers found the expression of this gene only in bone but not in 
other tissues. 
In this current study, FF-10 was expressed in non-metastatic CAb.D5 and AT-1; 
however, no expression was observed in other non-metastatic cell lines. Because there 
was no significant expression of FF-10 in any metastatic cell line but strong expression 
in non-metastatic CAb.D5 and AT-1 cell lines, it may be suggested that FF-10 prevents 
these cells from being metastatic. 
FH-2: (Rat cytokeratin 8): When FH-2 expression was examined, the 
most abundant expression was seen in non-metastatic AT-1 cells when compared to 
other cells (Figure 3.1.E). However, FH-2 was also expressed in metastatic AT-3 and 
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MATLu cells having a closer level of expression for each other. In non-metastatic 
CAb.D5 cells, FH-2 expression was seen less than others while it was the least in 
metastatic MATLyLu cells. 
Cytokeratins are the members of the intemediate multigene family and their 
expression change with the cell state (Simonishi et al. 2000). In addition, cytokeratins 
may be used as biomarkers to distinguish primary from metastatic carcinoma (Tot  
2002). Furthermore, cytokeratin expression patterns help to discriminate types of breast 
cancer (Bocker et al. 2002). In a research, it was demonstrated that FH-2 was poorly 
expressed or not expressed in the cells of metastatic human breast carcinoma (Zoli et al. 
1997). In another study, FH-2 was shown to be expressed significantly and highly in 
NSCLC (non-small-cell-lung cancer) than SCLC (small-cell-lung cancer) cells 
suggesting FH-2 may become a novel tumor marker especially in NSCLC patients. 
However, FH-2 expression was detected in both metastatic and non-metastatic rat cell 
lines.  
Finally, FH-2 expression was correlated with increased invasiveness in vitro and 
in vivo in many cancers (Schaafsma et al. 1993). According to the results of the present 
study, further investigations should be done to see its metastatic relevance. 
Rat SG-1:  When the rat SG-1 clone was investigated in different cell lines, it 
was expressed in non-metastatic cell CAb.D5, AT-1, and 13762 CT significantly 
(Figure 3.1.F). In comparison with the quantity of each expression level of rat SG-1 in 
cell lines, the most abundant expression was in CAb.D5 cells, and then in 13762 CT and 
AT-1 cells orderly. In other words, expression of SG-1 clone was consistant in three 
non-metastatic cell lines However, no expression was observed in metastatic cell lines 
LN4.D6 and MATLu. On the other hand, slight expression was detected in MATLyLu 
and AT-3 metastatic cell lines. 
Taken together, these results suggest that SG-1 may have tumor metastasis 
suppressor function. Transfection of metastatic cells with this gene and decrease in 
metastatic potential of the cells will confirm this result.  
Human SG-1: When human SG-1 was examined to see the expression levels 
in various cell lines, the housekeeping gene GAPDH and human SG-1 were interfered 
with each other (Figure 3.1.G). Therefore, they were examined in separate PCR 
reactions. Human SG-1 was mostly expressed in non-metastatic cell lines including 
CAb.D5, AT-1, MDA-MB-453, and HBL-100. Moreover, it was expressed in 
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metastatic MATLu cell line appearantly. No expression was observed in LN4.D6 
metastatic cell line.  
RB-8: (Neutrophil chemoattractant 2): According to the expression 
pattern of RB-8 clone in each cell line, it was seen that there was no correlation with 
metastatic characteristic (Figure 3.1.H). RB-8 was expressed in both metastatic and 
non-metastatic cell lines. The quantifications for expression levels of RB-8 in these cells 
were similar to each other or the same with each other. It was only not expressed in 
non-metastatic cells AT-1 and AT-2. 
RB-8 was demonstrated as expressed only in LN4.D6 cells and it was identified 
as a target to investigate its cell specific expression and relation with metastatic 
potential of cells (Gunes and Carlsen 2003). RB-8 was expressed in both non-metastatic 
and metastatic cell lines in this study. The reason for the expression of RB-8 in CAb.D5 
cells unlike the results of previous study might be due to the sensitivity of the 
techniques, Northern blot and RT-PCR, used in two different study. That is why it is not 
possible to indicate any metastatic relation of RB-8 clone before any other 
investigations have been done.  
RE-1: (Rat keratin (CK 5) mRNA): Among the cell lines that RE-1 was 
examined, it was only expressed in metastatic cell line LN4.D6 (Figure 3.1.I). There 
was no expression in other metastatic and non-metastatic cell lines. 
     Based on the results of this study, cell specific expression of RE-1 most 
likely is not involved in metastatic potential of LN4.D6 cells. However, it is possible 
that high level expression of this gene may have synergistic effect on the induction of 
metastatic formation in the cell. Similarly, Hansson et al. (2001) indicated that RE-1 
was highly expressed in malignant cells. 
RF-5: (Mouse keratin (epidermal) type 1): When RF-5 was examined 
in various cell lines, abundant expression was seen in LN4.D6 compared to CAb.D5 
cell line which has 1.4-fold less expression than that of LN4.D6. However, no 
expression was observed in other cell lines (Figure 4.1.J). In a previous study, RF-5 
expression was found 2-fold higher in metastatic cells than non-metastatic cells (Pencil 
et al. 1993). Therefore, upregulation and down regulation of cell specific expression 
level of RF-5 may be involved in metastatic potential of the cells. 
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Figure 3.1. Expression profiles of differentially expressed genes in different cell lines. 
GAPDH was used as internal control. Metastatic cell lines were designated as (+); non-
metastatic cell lines were designated as (-). 
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Even though expression levels of other differentially expressed genes were 
planned to analyze in a variety of cell lines, they could not be determined because 
primers which were designed for FC-7, FG-6, RB-9, RD-4 and RE-12 did not work. In 
addition, primers for human homolog of FF-10 were designed and tested in human 
tumor cell lines; however, it was expressed in every tumor cell line, examined and there 
was no significant difference in the expression level of FF-10 among the cell line (data 
not shown). 
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Table 3.1. Relative expression levels of mRNA of each differentially expressed gene.  
 
 
Clones                                                                Cell  lines 
                          
 
                          CAb.D5          LN4.D6            AT-1             AT-2            AT-3        MATLu         MATLyLu        MDA-MB-453       HBL-100          MCF-7                13762 CT 
 
FA-8                      116                  29                   64               NE               116               89                    54                       ND                        ND                     ND                          NE 
 
FC-1                      58                    39                   54               NE               43                 41                    32                       ND                        ND                     ND                          NE    
 
FC-6                     102                   31                   41               NE              NE                24                     20                       ND                       ND                     ND                           NE 
 
FF-10                     77                   29                   64               NE               24               NE                     29                       NE                         NE                     NE                           ND 
 
FH-2                      37                  NE                   61               NE               52                 48                    32                       NE                         NE                     NE                           ND 
 
Rat SG-1              99                   NE                   67               NE               NE              NE                    27                       ND                        ND                     ND                           78 
 
RB-8                     98                  110                  NE               NE               117             106                   100                      ND                        ND                    ND                          110       
 
RE-1                     NE                 121                   31                33                28               NE                   NE                       NE                        NE                     NE                           ND      
   
RF-5                    160                  234                  64                NE               13                20                     31                      ND                        ND                     ND                          ND      
 
 
Expression levels of differentially expressed genes were determined with RT-PCR analysis. The level of mRNA was quantified with 
gel documentation system (Vilber Lourmat, France) and normalized to the level of GAPDH, internal control. 
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3.2. Effects of Antioxidants and Zeolite on Cell Growth 
 
Because there is some evidence in the literature that antioxidants have effect on 
the growth of tumor cells, effects of green tea catechins, beta carotene, lycopene on the 
growth of CAb.D5 and LN4.D6 tumor cells as well as some other tumor cell lines were 
investigated. In addition, a silica mineral zeolite was used to treat cells to see the effect 
on the cell growth. 
 
3.2.1. Effects of Green Tea Catechins and Beta Carotene on Cell  
Growth 
 
The effects of green tea catechins and beta carotene on the cell growth of HeLa 
and DU145 cell lines were examined in variable concentrations. When we compared the 
effect of green tea catechins and beta carotene on HeLa cells, general inhibition of all 
those antioxidants on cell growth was seen at 50 µM concentration (Figure 3.3.1.A). 
Especially, at 100 µM and higher concentrations EGCG, EGC, GTC and beta carotene 
showed similar and most significant effect on cell growth. EGCG was the primarily 
inhibiting green tea catechin at lower concentrations in comparison with the others. 
Both EGCG and EGC showed a decrease on HeLa cell growth beginning from 10 µM 
concentration. GTC was the least effecting catechin on cell growth among other 
antioxidants. 
Another investigation for green tea catechins and beta carotene was done on the 
cell growth of prostate adenocarcinoma DU145 cells. Similar to the effects of those 
catechins and beta carotene on HeLa cells, EGCG, EGC, GTC and beta carotene 
effected growth of DU145 cells significantly at 50 µM concentration. Those four 
antioxidants effected DU145 cell growth most at 100µmole and higher concentrations 
with a range of similar value interval of each antioxidant. For DU145 cells, primarily 
inhibiting agents were EGCG effecting 2-fold and EGC effecting 1.5-fold among other 
antioxidants. 
Among green tea catechins, EGCG and EGC were mostly indicated as 
remarkable inhibitors against the growth of tumor cells like HTC116 human colorectal 
tumor cells (Uesato et al. 2001). In another study, EGCG was also reported as the most 
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effective apoptosis inducing polyphenol present in green tea (Azam et al. 2004). EGCG 
was used for human pancreatic carcinoma cells at 0, 25, 50, 100 and 200 µM/L. Growth 
of human pancreatic carcinoma cells were suppressed by EGCG in a doze-dependent 
manner (Moriatsu et al. 2002). EGCG was also significant in our results for cell growth 
inhibition. 
Many studies have shown an inverse relationship between beta carotene intake 
and various cancers. Levin et al. (1997) showed that beta carotene is an efficient 
antioxidant in inhibition of tumor cell growth in rats. In our experiments, beta carotene 
displayed average inhibition on tumor cell growth. 
Figure 3.2.A. Effects of green tea catechins and beta carotene on the growth of HeLa 
cells. Data are the average of duplicate samples. Difference among absorbance value of 
the duplicate samples were less than 2%. The experiment was repeated twice with the 
similar results. 
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Figure 3.2.B. Effects of green tea catechins and beta carotene on the growth of DU145 
cells. Data are the average of duplicate samples. Difference among the absorbance value 
of duplicate samples were less than 2%. The experiments were repeated twice with the 
similar results. 
 
3.2.2. Effects of Lycopene on Cell Growth 
 
Lycopene was the most effective on the growth of CAb.D5 cells compared to 
other cell lines. For example, at 3 µM concentration lycopene decreased the CAb.D5 
cell growth 1.7-fold compared to untreated cells and it remained almost at the same 
level at 6 µmole and 9 µM lycopene concentrations. Until 6µM concentration, lycopene 
decreased LN4.D6 cell growth regularly. When the effect of lycopene was compared 
with each of cell lines including CAb.D5, LN4.D6, DU145 and HBL-100; lycopene 
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Lycopene was shown to be a powerful inhibitor of endometrial, mammary 
(MCF-7), and lung (NCI-H 226) human cancer cells proliferation (Giovannucci et al. 
1995). Several groups have shown inhibition by lycopene of cancer cell growth on 
tissue culture experiments (Dorgan et al. 1998). It was demonstrated that lycopene 
inhibits mammary, endometrial, lung and leukemic cancer cell growth in a dose- 
dependent manner (IC50~ 2 µM) (Amir et al. 1999, Levy et al. 1995). It was most 
significant at 9 µM concentration of lycopene in our study for inhibiting the cell growth 
of treated cell lines. 
 
            
Figure 3.3. Effect of Lycopene on the growth of  CAb.D5, DU145, LN4.D6, HBL100 
cell lines. Data are the average of duplicate samples. Difference among the absorbance 
value of the duplicates were less than 2%. Experiment was repeated twice with the 
similar results. 
 
3.2.3. Effects of Zeolite on Cell Growth 
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metastatic and non-metastatic tumor cells LN4.D6 and CAb.D5 as well as some other 
cancer  cell lines. 
The inhibitory effect of zeolite on CAb.D5, LN4.D6, AT-1, and MATLyLu cells 
showed different levels at different concentrations. In CAb.D5 cells, zeolite decreased 
cell growth at 5mg/ml concentration and it was highly effective at 50mg/ml 
concentration when compared to untreated cells. For LN4.D6, decrease on cell growth 
was gradually seen at 0.5mg/ml, 5mg/ml, and 50mg/ml reaching 2.5-fold less than 
untreated LN4.D6 cells. The effect of zeolite on AT-1 cell growth was similar to 
LN4.D6. There was a gradual decrease but it was less than the decrease seen in LN4.D6 
cells. In MATLyLu and CAb.D5 cells, 0.5mg/ml concentration of zeolite showed no 
inhibitory effect. At 5mg/ml and 50mg/ml, zeolite decreased the cell growth of 
MATLyLu. Zeolite at 100mg/ml concentration showed opposite effect, increasing the 
cell growth in comparison with the untreated cells. 
Zeolite clinoptilolite has been demonstrated  to induce expression of  
P21WAF1/CIP1 and P27KIP1 tumor suppressor proteins. Thus, it inhibited cell growth of 
several cancer cell lines (Paveli et al. 2001).  The results of this current study is 
consistent with their results in which zeolite clinoptilolite inhibited the tumor cell 
growth at almost every concentration tested. However, zeolite at 100mg/ml 
concentration, it reconstituted the tumor cell growth and in some cases it increased the 
cell growth 1.6-fold and 1.8-fold in LN4.D6 and AT-1 cells compared to untreated cells 
(Figure 3.3.3). More detailed analysis of the cell culture content in the future studies 
will explain the reason for an increase of cell growth at 100mg/ml zeolite cocentration. 
It was also suggested as a potential regulator of immune system (Ueki et al. 1994, 
Aikoh et al. 1998). Finally, when we consider our results, there should be additional 
investigations of zeolite effect on cell growth. Further studies are necessary to reveal the 
effects of zeolites on cell growth. 
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Figure 3.4.  Effects of zeolite on the growth of different tumor cell lines at different 
concentrations. Data are the average of duplicate samples. Difference among the 
absorbance value of the duplicates were less than 2%. Experiment was repeated twice 
with the similar results. 
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comparison with untreated CAb.D5 cells, SG-1 expression was the highest in EGCG 
treated CAb.D5 cells. Relative levels of SG-1 mRNA were lower than the that of 
untreated CAb.D5 in EGC, GTC, and beta carotene treated cells (Figure 3.4.1.A). 
FF-10: According to the expression levels of FF-10 after catechin and beta 
carotene treatment, FF-10 was expressed in each EGCG, EGC, GTC and beta carotene 
treated cells at similar levels. However, the FF-10 expression was 1.3-fold less in 
antioxidant treated cells (Figure.3.5.B2). 
FH-2: In FH-2 expression after catechin and beta carotene treatment, there 
were similar results among EGCG, ECG, and beta carotene treated CAb.D5 cells. 
However, the amount of expression of treated cells were lower than the untreated 
CAb.D5 cells. FH-2 expression was inhibited 1.8-fold compared to untreated cells in 
GTC treated cells if we compare it with the other treated and untreated cells (Figure 
4.4.1.C). 
FA-8: When FA-8 expression was investigated in EGCG, ECG, GTC and beta 
carotene treated and untreated cells, the expression level of FA-8 was almost the same 
in all conditions (Figure 3.4.1.D). 
p53:  When p53 expression was investigated in EGCG, EGC, GTC and beta 
carotene and untreated CAb.D5 cells, gradual inhibition in p53 expression was observed 
(Figure 3.4.1.E). The expression levels increased in each antioxidant orderly. p53 was 
the lowest in EGCG treated CAb.D5 cells. The expression level in EGC treated cells 
were 1.25-fold higher than that of EGCG treated cells while p53 expression was also 
1.25-fold higher in GTC treated cells than the expression level of p53 in EGC treated 
CAb.D5 cells. Among treated cells, the highest expression potential was seen in beta 
carotene treated cells. p53 was highestly expressed in untreated cells when compared to 
treated cells. This result may suggest that EGCG, EGC, and GTC have inhibitory effect 
on the expression of p53 in CAb.D5 cells. 
EGCG was indicated to have anti-cancer activity through expression of several 
genes involved in cell proliferation and cell-matrix interactions (McLoughlin et al. 
2004). RT-PCR analysis of 20µM EGCG treatment on mouse calvarial primary 
osteoblastic cells resulted in reducing in expression of matrix metalloproteinases 
(MMPs) significantly. Also, EGCG significantly inhibited osteoblast formation at 
20µM concentration (Yun et al. 2004). Similar to previous studies, EGCG inhibited p53 
expression by 1.9-fold compared to untreated cells. 
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Figure 3.5. Expression profiles of differentially expressed genes in CAb.D5 cell line 
after treatment with green tea catechins. Lane 1: EGCG treated , Lane 2: EGC treated, 
Lane 3:  GTC treated, Lane 4: beta carotene treated, Lane 5: untreated CAb.D5 cells. 
 
3.3.2. Effects of Lycopene on Gene Expression 
            
Effect of lycopene on gene expression was examined among lycopene treated 
and untreated CAb.D5 cells for SG-1, FF-10 and FH-2 clones. According to the results, 
lycopene treated cells did not show any change in the expression of SG-1 clone. On the 
other hand, FF-10 expression was decreased almost 2-fold in lycopene treated CAb.D5 
cells in comparison with the untreated CAb.D5 cells. FH-2 expression was not inhibited 
after lycopene treatment considering the untreated CAb.D5 cells, either. 
In epidemiological studies, an inverse relation between lycopene and breast 
cancer risk was detected by some investigators (Zhang et al 1997, Jarvinen et al. 1997). 
Lycopene intake reduced 50% of mortality from cancers. The results of this study 
support the previous studies because SG-1 seems to have potential metastasis 
suppressor gene and its expression was not inhibited with lycopene. In contrast, FF-10 
expression was decreased by 2-fold with lycopene treatment compared to untreated 
cells. 
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A)      
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             Figure 3.6. Effect of lycopene on SG-1, FF-10 and FH-2 expression. Lane 1: 
untreated, Lane 2: lycopene treated CAb.D5 cells.  
     
3.3.3. Effects of Zeolite on Gene Expression 
 
The effect of zeolite on the expression of SG-1, FF-10, FH-2, FA-8 and p53 was 
determined after treatment of non-metastatic CAb.D5, AT-1 cells and metastatic 
LN4.D6, MATLyLu cells at different concentrations of zeolite. The identification of 
gene expression effect was achieved by RT-PCR analysis. 
When we compare the results of gene expression levels of zeolite treated cells 
with untreated cells, it was easily seen that there was no significant difference among 
them. Zeolite was reported to induce expression of  p21WAF1/CIP1 and p27KIP1 tumor 
suppressor proteins (Paveli et al. 2001). Therefore, our results are not consistent with 
the results of Paveli et al. (2001). In the literature, zeolite effect on gene expression is 
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not widely investigated. There should be detailed studies done for gene expression 
effect of zeolite trying different concentrations. 
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E)     1) 
 
 
                                                                   
         2) 
 
 
 
 
 
 
 
 
 
Figure 3.7.  Expression profiles of differentially expressed genes in CAb.D5 cell line 
after treatment with zeolite. Lane 1:  0.5mg/ml zeolite treated, Lane 2: 
5mg/ml zeolite treated, Lane 3: 10mg/ml zeolite treated, Lane 4: 20 mg/ml 
zeolite treated, Lane 5: untreated CAb.D5 cell lines. 
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CHAPTER 4 
 
CONCLUSION AND FUTURE EXPERIMENTS 
 
 
Cancer progress through different and related histopathological stages. 
Progression occurs by the accumulation of genetic alterations and during this, changes 
in gene expression patterns occur. Mutational and expression analysis of tumor 
suppressor genes in the early tumorigenesis are important to indicate the role of these 
genes in metastatis and cancer progression. According to the heterogenity of tumor 
cells, in primary tumors, it is not possible to separate the cells with respect to their 
metastatic potentials.  However, rapid advances in cancer research provided scientists to 
investigate the gene expression changes at early and late stages of cancer progression.  
In the previous study there were eight cDNA clones identified in poorly 
metastatic CAb.D5 cell lines and six cDNA clones identified in highly metastatic 
LN4.D6 cell lines. In this study, expression profiles of these differentially expressed 
genes were investigated in a set of adenocarcinoma cell lines to indicate their metastatic 
association. Among the primers designed for differentially expressed genes, primers for 
FC-7, FG-6, RB-9, RD-4 and RE-12 did not work. Therefore, expression profiles of the 
other differentially expressed genes (FA-8, FC-1, FC-6, FF-10, FH-2, RB-8, RE-1, RF-
5 and SG-1) were examined in different adenocarcinoma cell lines.  
 cDNA clones designated with FF-10 and SG-1 were initially detected to be 
expressed in non-metastatic cell line CAb.D5. Their expression was generally observed 
in non-metastatic tumor cell lines in this study as well. In addition, the clones RB-8, 
RE-1 and RF-5 were expressed in metastatic LN4.D6 cell line in a previous study. 
However, RB-8 expression was observed in both metastatic and non-metastatic cell 
lines in this current study. RE-1 was exclusively expressed in LN4.D6 cell line 
compared to other metastatic and non-metastatic cell lines. RF-5 expression was 
detected in both CAb.D5 and LN4.D6 cell lines; however, RF-5 expression was almost 
1.5-fold higher in LN4.D6 cells. In contrast to other clones explained above, the clones 
FF-10 expression was observed only in non-metastatic CAb.D5 and AT-1 cell lines. 
Moreover, when SG-1 expression was examined in three pairs of metastatic and non-
metastatic rat adenocarcinoma cell lines, it was only expressed in non-metastatic cell 
lines. This result suggest that the clone SG-1 may have metastatic suppressor function. 
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In further studies, transfection of cDNA constructs of SG-1, FF-10, RE-1 and RF-5 will 
help to elucidate the function of these genes in the metastatic process. 
Many studies have been done on the effect of antioxidants on tumor and tumor 
metastatasis. In this present study, various tumor cells were treated with green tea 
catechins including EGCG, ECG, GTC, beta carotene, lycopene and additionally with 
zeolite. Different concentrations of antioxidants were used to treat the cells and MTT 
assay was performed to see their effects on the tumor cell growth. The effects of green 
tea catechin and beta carotene at different concentrations on tumor cell growth exhibited 
the similar pattern in which a significant decrease in the cell growth was observed at 
100 µM of EGCG and EGC. Cell growth gradually decreased after treatment with GTC 
and beta carotene. Among the green tea catechins EGC was the most effective on the 
inhibition of tumor cell growth. In addition, effect of lycopene on different tumor cell 
growth was examined and found that lycopene at 3 µM showed the significant effect on 
the inhibition of CAb.D5 cell growth. Moreover, effect of zeolite on cell growth was 
investigated and shown that at 5mg/ml and 50mg/ml concentrations, zeolite exhibited 
an inhibitory effect on the growth of cell lines examined. However, at 100mg/ml, 
zeolite induced the tumor cell growth. Further study is required to have more results for 
the effect of zeolite on cell growth. 
Finally, the effect of green tea catechins, beta carotene, lycopene, and zeolite 
was investigated on the expression of differentially expressed genes. Compared to other 
green tea catechins, EGCG did not inhibit SG-1 expression in fact it increased the 
expression 1.2-fold compared to untreated cells. 
It has been suggested that in the next decade, there will be serious developments 
in cancer research by the help of new data on cancer genetics, epigenetics, genomics 
and gene expression. Continued work with model organisms will hopefully provide 
answers to many questions especially in the molecular mechanisms of cancer. The 
identification of genes involved in cancer progression will enhance understanding the 
biology of this process as well as provide new targets for early diagnosis and treatment 
of cancer. As gene expression profiling gave rise to the subclassification of tumors, our 
results will be a step for indicating the metastatic relevance of these different tumor 
types. Investigations on antioxidant effect is a developing area that may provide new 
drug discoveries, exploring chemopreventive agents and treatment approaches on 
cancer patients and in malignant situations.  
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In conclusion, except SG-1, metastatic relevance of other differentially 
expressed genes were not observed in different adenocarcinoma cell lines. However, it 
will be important to look at expression profiles of especially SG-1, FF-10, RE-1 and 
RF-5 in primary and secondary human tumors in order to confirm their metastatic 
relevance. 
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APPENDIX A 
 
Cell Lines and Their Metastatic Characteristics 
 Rat Mammary Adenocarcinoma Cell Lines 
CAb.D5: Poorly metastatic 
LN4.D6: Metastatic 
13762 CT: Non-metastatic 
13762 WT: Metastatic 
 
 Rat Prostate Adenocarcinoma Cell Lines 
AT-1: Non-metastatic 
AT-2: Non-metastatic 
AT-3: Metastatic 
MATLu: Metastatic 
MATLyLu: Metastatic 
 
 Human Mammary Adenocarcinoma Cell Lines 
MDA-MB-453: Poorly metastatic 
MCF-7: Non-metastatic 
HBL-100: Non-metastatic 
T47D: Non-metastatic 
 
 Human Prostate Adenocarcinoma Cell Lines 
LNCap: Non-metastatic 
PC-3: Poorly metastatic (buna metastatic deniyor bazı makalelerde) 
DU145: Metastatic                  
                                                                                                
 Human Cervix Adenocarcinoma Cell Line and Human Colon 
Adenocarcinoma 
HeLa: Metastatic                                                                                               
 
                                                                                                                         
AA1 
